Craig A. Dionne, PhD
President, CEO, CFO and Chairman of the Board
Craig A. Dionne, PhD, is one of our founders and has served on our board since November 2003. He has over 25 years of experience in the pharmaceutical industry, including direct experience in identifying promising oncology treatments and bringing them through the clinic. He served for several years as VP Discovery Research at Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, where he was responsible for its oncology and neurobiology drug discovery and development programs. Dr. Dionne also served as Executive Vice President at the Prostate Cancer Research Foundation. In addition to extensive executive experience, Dr. Dionne's productive scientific career has led to six issued patents and co-authorship of many scientific papers. Dr. Dionne received his PhD from the University of Texas at Austin in 1984.
Peter E. Grebow, PhD
Peter E. Grebow, PhD, joined the board in May 2012. He currently is President and founder of P.E. Grebow Consulting, Inc., which he formed in 2011. He has also served as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. since October 2013. Before becoming a director at GenSpera, Dr. Grebow held several key positions with Cephalon, Inc., including Executive Vice President of Cephalon Ventures, Executive Vice President of Technical Operations, Senior Vice President of Worldwide Business Development and Senior Vice President of Drug Development. Prior to joining Cephalon, Dr. Grebow served as Vice President Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., and as director of Optimer Pharmaceuticals (NASDAQ: OPTR) . Since 2011, he has held directorships at Q Holdings, Inc., and Complexa, Inc. Dr. Grebow received his PhD in physical biochemistry from the University of California, Santa Barbara, in 1973.
Bo Jesper Hansen, MD, PhD
Bo Jesper Hansen, MD, PhD, joined the GenSpera board in August 2010. He is currently the Executive Chairman of the Board of Swedish Orphan Biovitrum AB (STO: SOBI), an international growth company specializing in the development, registration, marketing and distribution of pharmaceutical drugs for rare and life-threatening diseases. Dr. Hansen has held this position since January 2010, as a result of the merger of Swedish Orphan International AB Group and Biovitrum. Prior to the merger, Dr. Hansen served from 1998 to 2010 in numerous positions with Swedish Orphan International AB Group, including CEO, President, and Director of the Board, where his responsibilities included establishment, development and expansion of the company's operations in Europe, Japan, the Americas, and Australia. Dr. Hansen also serves on the boards of CMC AB, Orphazyme ApS, Newron (SIX; NWRN), TopoTarget A/S (NASDAQ OMX: TOPO), Hyperion Therapeutics Inc. (NASDAQ, HPTX), and Ablynx NV (ABLX). Dr. Hansen holds a Doctor of Medicine degree from the University of Copenhagen with a specialty in urology and completed his PhD in 1996.
Scott V. Ogilvie joined our board in February 2008. He currently is President of AFIN International, Inc., a private equity/business advisory firm, which he founded in 2006. Additionally, Mr. Ogilvie has served as a partner of Wirthlin Worldwide International, a private strategic advisory and M&A firm, since September 2011. From August 2006 to December 2009, he was President and CEO of Gulf Enterprises International, Ltd., a company that brings strategic partners, expertise and investment capital to the Middle East and North Africa. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment management firm. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate board experience in finance, real estate and technology companies. Mr. Ogilvie currently serves on the board of directors of Neuralstem, Inc. (NYSE AMEX:CUR), and Research Solutions, Inc. (OTCBB: RSS). Mr. Ogilvie has also served on the board of Directors of Preferred Voice Inc. (OTCQB: PRFV), Innovative Card Technologies, Inc. (ORTBB: INVO), National Healthcare Exchange, Inc (OTCBB: NHXS) and Derycz Scientific, Inc. (OTCQB: DYSC).
Russell Richerson, PhD
Russell B. Richerson, PhD COO and Corporate Secretary
Russell B. Richerson, PhD, joined GenSpera in September 2009. He has over 25 years of experience in the Biotechnology/Diagnostics industry, including 11 years at Abbott Laboratories in numerous management roles. He also has extensive experience in senior research and development positions at companies such as Boehringer Mannheim, Du Pont, Prometheus Laboratories, Ventana Medical Systems, and the Molecular Profiling Institute. Dr. Richerson currently serves on the board of the International Genomics Consortium (IGC), a non-profit medical research organization located in Phoenix, Arizona. Dr. Richerson received his PhD from the University of Texas at Austin in 1983
John T. Isaacs, PhD
Chief Scientific Advisor, Chairman of the Science Advisory Board and Co-Founder
John T. Isaacs, PhD, is Professor of Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and a Professor in the Department of Urology at the Johns Hopkins School of Medicine in Baltimore, Maryland. He is the Editor-in-Chief of the journal The Prostate and is on the editorial board of the journals Cancer and Metastasis Review and OncoScience. He previously served as president of Society for Basic Urological Research and on the Experimental Therapeutics Study Section for NIH.
Samuel R. Denmeade, MD
Chief Clinical Advisor and Co-Founder
Samuel R. Denmeade, MD, is Professor of Oncology, Urology and Pharmacology and is the co-director of the Prostate Cancer Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His laboratory focuses on the development of targeted therapies for the treatment of prostate cancer. He has developed several prodrug therapies that are activated by prostate cancer specific proteases and has published over 50 papers in this area. Dr. Denmeade is a Board Certified Medical Oncologist and currently serves as the Principal Investigator on a number of prostate cancer clinical trials. He is on the Editorial Board of the journal The Prostate.
Søren Brøgger Christensen, PhD
Scientific Advisory Board Member
Søren Brøgger Christensen, PhD, is Professor, Department of Drug Design and Pharmacology, The Faculty of Health and Medical Sciences at the University of Copenhagen in Denmark and is internationally recognized for his work in the isolation, identification and structural modification in order to optimize the drug ability of natural products with significant biological activities. He was the first to elucidate the chemical structure of thapsigargin and his lab is productively engaged in exploring further derivatives of this bioactive compound. Dr. Christensen has co-authored over 160 scientific publications and is co-inventor on several key patents in GenSpera's intellectual property portfolio.